David Teng-Yi Huang

Senior Director of Medicinal Chemistry & ADC Enabling Technologies
OBI Pharma 
 

​

David Teng-Yi Huang, Ph.D., is a distinguished chemist with deep expertise in carbohydrate chemistry and its translational application to Antibody Drug Conjugate (ADC) technology. As Senior Director of Medicinal Chemistry and ADC Enabling Technologies at OBI Pharma, Dr. Huang plays a pivotal role in advancing the company's cutting-edge ADC platforms, including GlycOBI®, ThiOBI®, EndoSymeOBI®, and HYPrOBI™.
 
Dr. Huang’s research focuses on enabling site-specific, homogeneous ADC development through innovative linker-payload designs and glycoengineering strategies. Under his leadership, OBI has established a differentiated ADC technology portfolio that addresses key limitations of traditional conjugation methods—enhancing therapeutic index, manufacturability, and platform scalability.
 
He has spearheaded the development of multiple clinical and preclinical ADC candidates, including dual-payload and bispecific ADCs. His efforts have significantly contributed to OBI's growing reputation as a leader in next-generation ADC solutions with best-in-class conjugation technologies.
 
Dr. Huang earned his Ph.D. in Chemistry from National Tsing Hua University in Taiwan, where he specialized in synthetic carbohydrate chemistry. He further honed his scientific expertise as a postdoctoral fellow at the Genomic Research Center, Academia Sinica, focusing on glycoscience for biomedical applications.
 
In addition to his scientific leadership, Dr. Huang is a key contributor to OBI’s intellectual property portfolio and actively participates in global business development initiatives, fostering partnerships and driving the strategic expansion of OBI’s ADC pipeline.​
​
​

Speech title & Synopsis

Reimagining ADC Design via GlycOBI®: A Multi-Platform Technology for Site-Specific and Dual-Payload Conjugates

Despite the clinical promise of ADCs, many remain limited by heterogeneous conjugation, unstable linkers, and restricted payload flexibility. OBI Pharma addresses these challenges through the Obrion™ ADC Enabling Technology, which includes GlycOBI®, a site-specific glycan engineering platform that enables homogeneous, stable ADCs with improved pharmacokinetics and therapeutic index.
 
This presentation introduces GlycOBI DUO™, our next-generation platform for dual-payload ADCs, powered by HYPrOBI™—a hydrophilic, modular linker system designed for controlled payload release and precise DAR control. Together, GlycOBI DUO™ and HYPrOBI™ enable programmable installation of two distinct payloads at defined ratios and conjugation sites.
 
We will highlight how linker structure, DAR, and conjugation site impact payload release kinetics and in vivo performance. Comparative studies with traditional conjugation methods demonstrate GlycOBI DUO™’s advantages in tumor targeting, payload synergy, and manufacturability.
 
This modular system supports rapid prototyping and is compatible with bispecifics and other next-generation antibody formats. GlycOBI DUO™ represents a transformative advancement in ADC design, offering new opportunities to rationally engineer next-generation therapeutics with enhanced precision, efficacy, and safety.